Masaki Doi
Plus aucun poste en cours
Profil
Masaki Doi is a former President & CEO of Astellas Venture Management LLC.
He also served as a Director at PROMETHERA Biosciences SA. Prior to that, he was an Executive Officer & Head of Vaccine Promotion Project at Astellas Pharma,.
Inc. Doi holds an undergraduate and doctorate degree from the University of Tokyo.
Anciens postes connus de Masaki Doi
| Sociétés | Poste | Fin |
|---|---|---|
| ASTELLAS PHARMA INC. | Corporate Officer/Principal | - |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Directeur/Membre du Conseil | - |
Astellas Venture Management LLC
 Astellas Venture Management LLC Investment ManagersFinance Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Pharma Inc founded in 2000. The firm is headquartered in San Francisco, California. | President | - |
Formation de Masaki Doi
| University of Tokyo | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ASTELLAS PHARMA INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Astellas Venture Management LLC
Astellas Venture Management LLC Investment ManagersFinance Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Pharma Inc founded in 2000. The firm is headquartered in San Francisco, California. | Finance |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Health Technology |
